Fidelity Parent FMR Holds 6% Of Thermo Fisher, Or 22.3 Million Shares

FMR's passive ownership filing puts its Thermo Fisher stake at 22,261,362.05 shares as of September 30.

Share
Fidelity Parent FMR Holds 6% Of Thermo Fisher, Or 22.3 Million Shares

FMR LLC, the parent of Fidelity's fund and trust businesses, held 22,261,362.05 shares of Thermo Fisher Scientific, or 6% of the common stock, as of September 30, according to a passive ownership filing (Schedule 13G) filed Thursday. Abigail P. Johnson, FMR's chairman and CEO, is a joint reporting person.

Who holds the 22.3 million shares

FMR has sole voting power over 20,235,010.53 of the shares and no shared voting power. Johnson has no voting power individually, the filing shows.

The holdings are spread across Fidelity units. An exhibit lists FIAM, Fidelity Management & Research Company, Fidelity Management Trust Company, Strategic Advisers and several other entities among the beneficial owners. The filing says no other single person's interest in the stock exceeds 5% of the total outstanding.

FMR certified that the shares were bought and are held in the ordinary course of business, not to change or influence control of Thermo Fisher. The joint filing agreement is dated November 4.

The Johnson family's grip on FMR

The exhibit says Johnson family members are the predominant owners of FMR's Series B voting shares, which carry 49% of FMR's voting power. Those holders vote the shares as a bloc under a shareholders' agreement, following the majority of Series B shares, and the family may be deemed a controlling group of FMR under the Investment Company Act of 1940.

A stock fund managers like

Thermo Fisher supplies instruments, reagents, consumables, diagnostic tests and lab products, plus outsourced drug development and manufacturing, to pharmaceutical and biotech companies, hospitals, universities and government agencies. Shares traded at $680.37 in Thursday trading, down about 4% from the prior close of $706.16, giving it a market value of $261.6 billion.

Buffalo Growth Fund said in its third-quarter letter the stock gained 27% in the quarter and that it trimmed its position after the run. Baron Health Care Fund cited improving pharma and biotech spending and stronger bioproduction results. S&P Global Ratings assigned an "A-" rating to the company's new senior unsecured debt on November 2.

Johnson family members' 49% of FMR's voting power sits behind the 6% Thermo Fisher position.

Sources

More on Thermo Fisher Scientific

All Thermo Fisher Scientific (TMO) coverage →